These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 28959938)

  • 1. Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study.
    Gagini T; de Oliveira Schubach A; de Fatima Madeira M; Maria Valete-Rosalino C; Fernandes Pimentel MI; da Silva Pacheco R
    Parasite; 2017; 24():34. PubMed ID: 28959938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
    Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
    J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
    Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
    Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro characterization of Leishmania (Viannia) braziliensis isolates from patients with different responses to Glucantime(®) treatment from Northwest Paraná, Brazil.
    Fernandes AC; Pedroso RB; de Mello TF; Donatti L; Venazzi EA; Demarchi IG; Aristides SM; Lonardoni MV; Silveira TG
    Exp Parasitol; 2016 Aug; 167():83-93. PubMed ID: 27181585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.
    Perez-Franco JE; Cruz-Barrera ML; Robayo ML; Lopez MC; Daza CD; Bedoya A; Mariño ML; Saavedra CH; Echeverry MC
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004739. PubMed ID: 27243811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.
    Teva A; Porrozzi R; Oliveira-Neto MP; Grimaldi GJ
    J Parasitol; 2005 Aug; 91(4):976-8. PubMed ID: 17089782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil.
    Romero GA; de la Glória Orge Orge M; de Farias Guerra MV; Paes MG; de Oliveira Macêdo V; de Carvalho EM
    Acta Trop; 2005 Jan; 93(1):49-56. PubMed ID: 15589797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.
    Zauli-Nascimento RC; Miguel DC; Yokoyama-Yasunaka JK; Pereira LI; Pelli de Oliveira MA; Ribeiro-Dias F; Dorta ML; Uliana SR
    Trop Med Int Health; 2010 Jan; 15(1):68-76. PubMed ID: 19874570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
    Romero GA; Guerra MV; Paes MG; Macêdo VO
    Am J Trop Med Hyg; 2001 Nov; 65(5):456-65. PubMed ID: 11716098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania (Viannia) braziliensis genotypes identified in lesions of patients with atypical or typical manifestations of tegumentary leishmaniasis: evaluation by two molecular markers.
    Baptista C; Schubach AO; Madeira MF; Leal CA; Pires MQ; Oliveira FS; Conceição-Silva F; Rosalino CM; Salgueiro MM; Pacheco RS
    Exp Parasitol; 2009 Apr; 121(4):317-22. PubMed ID: 19135053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro sensitivity of paired Leishmania (Viannia) braziliensis samples isolated before meglumine antimoniate treatment and after treatment failure or reactivation of cutaneous leishmaniasis.
    Baptista C; Miranda Lde F; Madeira Mde F; Leon LL; Conceição-Silva F; Schubach Ade O
    Dis Markers; 2015; 2015():943236. PubMed ID: 25802480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated cutaneous leishmaniasis caused by Leishmania braziliensis in Southern Brazil.
    Membrive NA; Kazuma FJ; Silveira TGV; Teixeira JJV; Reinhold-Castro KR; Teodoro U
    Rev Inst Med Trop Sao Paulo; 2017 Jun; 59():e37. PubMed ID: 28591265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis.
    Fernández OL; Rosales-Chilama M; Sánchez-Hidalgo A; Gómez P; Rebellón-Sánchez DE; Regli IB; Díaz-Varela M; Tacchini-Cottier F; Saravia NG
    PLoS Negl Trop Dis; 2024 May; 18(5):e0012156. PubMed ID: 38709850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular epidemiology and in vitro evidence suggest that Leishmania braziliensis strain helps determine antimony response among American tegumenary leishmaniasis patients.
    Silva SC; Guimarães LH; Silva JA; Magalhães V; Medina L; Queiroz A; Machado PRL; Schriefer A
    Acta Trop; 2018 Feb; 178():34-39. PubMed ID: 29042262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of drug resistance related genes as candidate markers for treatment outcome prediction of cutaneous leishmaniasis in Brazil.
    Torres DC; Ribeiro-Alves M; Romero GA; Dávila AM; Cupolillo E
    Acta Trop; 2013 May; 126(2):132-41. PubMed ID: 23416123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of imported New World cutaneous leishmaniasis in Germany.
    Harms G; Scherbaum H; Reiter-Owona I; Stich A; Richter J
    Int J Dermatol; 2011 Nov; 50(11):1336-1342. PubMed ID: 22004484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
    de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
    J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. kDNA minicircle signatures of Leishmania (Viannia) braziliensis in oral and nasal mucosa from mucosal leishmaniasis patients.
    de Oliveira FS; Valete-Rosalino CM; Schubach Ade O; Pacheco Rda S
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):361-5. PubMed ID: 20226327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
    Arevalo J; Ramirez L; Adaui V; Zimic M; Tulliano G; Miranda-Verástegui C; Lazo M; Loayza-Muro R; De Doncker S; Maurer A; Chappuis F; Dujardin JC; Llanos-Cuentas A
    J Infect Dis; 2007 Jun; 195(12):1846-51. PubMed ID: 17492601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphism in Leishmania (Viannia) braziliensis detected in mucosal leishmaniasis of HIV-infected and non-HIV-infected patients.
    de Oliveira FS; Valete-Rosalino CM; Schubach Ade O; Madeira Mde F; Pacheco Rda S
    Trans R Soc Trop Med Hyg; 2012 Nov; 106(11):683-7. PubMed ID: 22954800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.